Sequelae of Guillain-Barré syndrome
ICD-10 G65.0 is a billable code used to indicate a diagnosis of sequelae of guillain-barré syndrome.
Sequelae of Guillain-Barré syndrome (GBS) refers to the residual effects that persist after the acute phase of the syndrome has resolved. GBS is an autoimmune disorder characterized by rapid-onset muscle weakness and can lead to varying degrees of paralysis. The sequelae may include persistent weakness, sensory disturbances, and fatigue, which can significantly impact a patient's quality of life. Neurological assessments often reveal abnormalities in reflexes and muscle strength, and patients may experience neuropathic pain or dysautonomia. Treatment for sequelae typically involves physical therapy, occupational therapy, and pain management strategies. The prognosis varies, with some patients experiencing complete recovery while others may have long-term disabilities. Accurate coding of G65.0 is essential for appropriate management and reimbursement, as it reflects the ongoing challenges faced by patients recovering from GBS.
Detailed neurological assessments, including muscle strength tests, reflex evaluations, and sensory examinations.
Patients presenting with residual weakness, sensory changes, or pain following GBS.
Neurologists must ensure that all sequelae are documented to support the use of G65.0.
Progress notes detailing therapy interventions, patient response, and functional improvements.
Patients undergoing rehabilitation for muscle weakness and mobility issues post-GBS.
Therapists should document specific functional goals and progress to support coding.
Used for initial assessment of a patient with sequelae of GBS.
Detailed evaluation of physical function and limitations.
Physical therapists should document specific goals and progress.
Common long-term effects include muscle weakness, sensory disturbances, fatigue, and pain. These sequelae can vary significantly among individuals.
